SIGA Technologies, Inc.SIGA
Price as of · delayed, not real-time
A biopharmaceutical company focused on developing and commercializing products to address serious infectious diseases, with its lead product, TPOXX, approved for the treatment of smallpox. The company holds a strategic stockpile contract with the U.S. government, making its revenue stream closely tied to federal procurement decisions. Investors track SIGA for its government contracts, potential antiviral applications, and its position as a key player in medical countermeasures.
Congressional Interest in SIGA Technologies, Inc. (SIGA)
1 member of Congress has disclosed 1 trade in SIGA Technologies, Inc. (SIGA), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Who in Congress Is Trading SIGA?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2016-12-02 | JOHN K. DELANEY | buy | $1K-$15K |